2019 novel coronavirus (SARS-CoV-2) is a life-threatening infectious disease caused by SARS-CoV-2. Currently, no effective drug exists to treat SARS-CoV-2 infection. It has led to the empiric use of broad-spectrum antiviral agents in affected patients in several countries. Creative Biolabs has established excellent platforms for drug development. We provide a variety of antiviral agent development services to meet the diverse needs of our customers.
Neuraminidase inhibitors (NAIs), such as oseltamivir, zanamivir, and peramivir, are the current agents of choice against influenza A and B viruses. The NAIs interfere with the release of progeny influenza virus from infected host cells, a process that prevents the infection of new host cells and thereby halts the spread of infection in the respiratory tract. Oseltamivir is developed through modifications to the sialic acid analogue framework that allows the drug to be used orally. Zanamivir is administered by oral inhalation, which delivers the drug directly to the respiratory tract. Peramivir has a cyclopentane ring and features of both zanamivir and oseltamivir, the C4-guanidino substitution and a hydrophobic side chain, respectively. It is only effective if administered intravenously.
SARS-CoV-2 is a respiratory illness that has recently been identified in several countries. The primary way that the transmission of SARS-CoV-2 occurs is mainly by close person-to-person contact, or by direct contact with infectious materials, such as respiratory secretions, from a person who has SARS-CoV-2. It is also possible that SARS-CoV-2 can be spread more broadly through the air or by other ways that are currently not known. Threatened by such a severe disease, scientists at Creative Biolabs are facing a significant challenge, i.e., how to provide professional knowledge and technology that will contribute to effective drugs against SARS-CoV-2.
Fig.1 Mechanism of action of neuraminidase inhibitors.
Structure-based drug design (SBDD) methods have played a critical role in the discovery of antiviral agents, and these methods allowed the prediction of binding affinities of a series of molecules that belong to the same chemical class or close analogues. At Creative Biolabs, based on the amount of NAIs synthesized and the progress in computational chemistry, we have derived optimized quantitative structure-activity relationship (QSAR) models with the purpose of proposing a presumable model for identifying effective inhibitors and designing new compounds. The SBDD methods provide important information for the exploitation and utilization of compounds as new inhibitors for SARS-CoV-2 treatment.
Creative Biolabs has focused on the development of antiviral agents for years, and we whole-heartedly cooperate with you to accomplish our shared goals. Our team provides you with outstanding support and meets your specific needs with a professional technology platform. If you are interested in our services, please contact us for more details.For Research Use Only. We do not provide direct services or products for patients.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.